Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "IP"

10224 News Found

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
Drug Approval | January 17, 2023

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22


Global Hospital's hand transplant recipients to participate in Tata Mumbai Marathon 2023
Healthcare | January 16, 2023

Global Hospital's hand transplant recipients to participate in Tata Mumbai Marathon 2023

Monika and Prathmesh’s determination to participate in the Dream Run to increase awareness serves as a testament to life changing effects of organ transplants and importance of organ donation


Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules
Drug Approval | January 16, 2023

Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India


Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets
Drug Approval | January 13, 2023

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults


Moderna announces advances across mRNA pipeline
News | January 10, 2023

Moderna announces advances across mRNA pipeline

Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Harbor Healthcare advises a California long-term care pharmacy on its sale & strategic partnership
News | January 04, 2023

Harbor Healthcare advises a California long-term care pharmacy on its sale & strategic partnership

The strategic acquirer maintains a nationwide presence in the LTC pharmacy space


Survival Technologies files DRHP with SEBI for Rs 1,000 crore IPO
News | January 02, 2023

Survival Technologies files DRHP with SEBI for Rs 1,000 crore IPO

The company is one of the most profitable companies manufacturing speciality chemicals in India


Cipla EU to invest € 15 million in Ethris
News | December 30, 2022

Cipla EU to invest € 15 million in Ethris

Cipla and Ethris partner for the development of mRNA-based therapies


NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData
News | December 27, 2022

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData

China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.